Northern Trust’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-69,029
Closed -$9.66K 4500
2024
Q1
$9.66K Hold
69,029
﹤0.01% 4390
2023
Q4
$10K Hold
69,029
﹤0.01% 4419
2023
Q3
$12.1K Hold
69,029
﹤0.01% 4386
2023
Q2
$215K Buy
69,029
+39,763
+136% +$118K ﹤0.01% 3800
2023
Q1
$74.9K Hold
29,266
﹤0.01% 4155
2022
Q4
$43.6K Hold
29,266
﹤0.01% 4311
2022
Q3
$51K Buy
29,266
+11,091
+61% +$15.7K ﹤0.01% 4319
2022
Q2
$24K Hold
18,175
﹤0.01% 4596
2022
Q1
$43K Hold
18,175
﹤0.01% 4566
2021
Q4
$83K Hold
18,175
﹤0.01% 4475
2021
Q3
$147K Buy
18,175
+3,380
+23% +$29K ﹤0.01% 4294
2021
Q2
$145K Sell
14,795
-80,150
-84% -$651K ﹤0.01% 4263
2021
Q1
$838K Sell
94,945
-3,818
-4% -$41.9K ﹤0.01% 3653
2020
Q4
$1.01M Sell
98,763
-5,182
-5% -$56.7K ﹤0.01% 3517
2020
Q3
$940K Sell
103,945
-240
-0.2% -$1.9K ﹤0.01% 3417
2020
Q2
$744K Buy
104,185
+70,774
+212% +$751K ﹤0.01% 3457
2020
Q1
$317K Buy
33,411
+441
+1% +$5.68K ﹤0.01% 3559
2019
Q4
$434K Buy
+32,970
New +$402K ﹤0.01% 3592

Other funds holding GRTX

Northern Trust's GRTX Position: Q2 2024 in Review

Northern Trust sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 69,029 shares — an estimated $9.66K sold.

Northern Trust first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $1.01M in Q4 2020. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.

  • Northern Trust reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Northern Trust sold 69,029 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $9.66K.
  • Northern Trust first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
  • Northern Trust's Galera Therapeutics, Inc. Common Stock position peaked at $1.01M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Northern Trust's 13F filing for Q2 2024, filed 14 Aug 2024.